Navigation Links
Technique May Let More Women Use Tamoxifen
Date:2/23/2009

30% of breast cancers currently don't respond to this type of estrogen-linked drug

MONDAY, Feb. 23 (HealthDay News) -- Researchers have found a way to "switch on" estrogen sensitivity in breast tumor cells, thereby making them vulnerable to the breast cancer drug tamoxifen.

If successful, the technique might someday allow breast cancer patients who don't respond to tamoxifen to benefit from the drug.

"We're excited by the results," said study author Caroline Ford, a member of the department of cell and experimental pathology at Lund University in Malmo, Sweden. "This has implications for the 30 percent of breast cancer patients who are estrogen-receptor negative who currently have a poor prognosis."

Not only might these tumors become amenable to tamoxifen, but they may also respond to other "endocrine" treatments such as aromatase inhibitors, which also interfere with estrogen production in the body.

"We are currently investigating this," Ford said.

The findings may also provide alternatives for the group of women who start out estrogen receptor-positive but later become negative and for whom treatments stop working.

The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

As Ford noted, a large minority of patients have breast cancer tumors that do not express estrogen receptors. Not only does this make them unresponsive to a variety of treatments now available for estrogen receptor-positive malignancies, but it indicates a more aggressive cancer in general.

Tamoxifen, which has been a gold standard of breast cancer treatment for decades, works by binding to the estrogen receptor. If there is no receptor, however, tamoxifen becomes useless.

Any means of allowing the three out of 10 women whose cancers don't respond to tamoxifen and other endrocrine therapies would be a big advance, experts say.

"[Research] groups have been looking to restore positivity, to open the door to treatment with tamoxifen and aromatase inhibitors," said Dr. Minetta Liu, a translational researcher and breast oncologist at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, D.C. The Swedish team now "have a molecule suggested that may, in fact, succeed. The findings are very exciting," he said.

So far, however, these promising results have only been seen in the lab and would need to be confirmed in animal models. If those experiments are successful, human trials would come next.

So how does the new technique work? In prior trials, researchers had noticed an association between cells that didn't express the estrogen receptor and a loss of expression of Wnt-5a, a key signaling protein.

This led to a theory that Wnt-5a might regulate estrogen receptor levels and, in fact, this seemed to be the case. Re-establishing Wnt-5a signaling resulted in higher estrogen receptor levels in estrogen receptor-negative cells.

But, the authors pointed out, Wnt-5a is probably too large a molecule to be administered directly to patients.

But Foxy-5, a smaller molecule and a Wnt-5a analog (look-alike) developed in the laboratory, did the same job as effectively, the team said.

Ford, along with a co-author of the paper, has filed a patent for the effects of the Foxy-5 peptide on estrogen receptors.

In related research, another study in the same issue of PNAS found that a protein called lipocalin 2 can indicate how invasive a breast cancer is likely to be. Better yet, levels of the protein can be measured in urine.

Apparently, lipocalin 2 decreases estrogen receptor levels, which indicates the presence of more aggressive cancer, according to researchers at Children's Hospital Boston.

Testing for the protein could help doctors and patients decide when more aggressive treatments might be appropriate.

More information

There's more on estrogen receptors at the U.S. National Cancer Institute.



SOURCES: Caroline Ford, Ph.D., department of cell and experimental pathology, Lund University, Malmo, Sweden; Minetta Liu, M.D., translational researcher/breast oncologist, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; Feb. 23-27, 2009, Proceedings of the National Academy of Sciences


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Eye-staining technique offers early detection for dry eye syndrome
2. New technique detects specific chromosomal damage, may indicate lung cancer risk
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
5. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
6. Radiation therapy technique reduces length of prostate cancer treatment
7. Radiation therapy technique reduces length of prostate cancer treatment
8. IVF technique enables pregnancy without multiple births, Stanford researchers find
9. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
10. UCLA doctor develops new technique to treat varicose veins
11. New technique improves purity of medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Technique May Let More Women Use Tamoxifen
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
Breaking Medicine Technology: